Sanofi - ADR

Sanofi - ADR

SNY

Market Cap$136.3B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Sanofi - ADRSanofi - ADR15.63.01%11%20.3

Earnings Call Q3 2024

October 25, 2024 - AI Summary

**Strong Sales Performance**: Sanofi reported Q3 2024 sales of EUR 13.4 billion, representing a 16% increase in constant currency (CER) and an estimated 11% increase excluding phasing benefits. This indicates a robust underlying growth across their diverse portfolio, particularly driven by Dupixent's strong volume growth.
**Dupixent Growth and Market Expansion**: Dupixent generated sales of almost EUR 3.5 billion for the quarter and is expected to reach around EUR 13 billion for the full year 2024. Recent approvals for COPD in major markets (US and China) are set to enhance its growth trajectory, and strong demand is anticipated due to unmet needs in respiratory conditions.
**Vaccines and Newly Launched Products**: The Vaccines business grew by 26%, benefiting from early season flu sales and Beyfortus's rollout, which is projected to achieve around EUR 1.5 billion in sales for 2024. Newly launched medicines collectively generated substantial revenue, indicating a successful launch strategy that positions Sanofi well for future growth.

Exclusive for Stockcircle Pro members

Sign upSign Up
$62.00

Target Price by Analysts

16.4% upsideSanofi Target Price DetailsTarget Price
$85.31

Current Fair Value

60.2% upside

Undervalued by 60.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$136.30 Billion
Enterprise Value$151.65 Billion
Dividend Yield$2.04 (3.00865573248845%)
Earnings per Share$2.15
Beta0.42
Outstanding Shares2,497,600,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio15.58
PEG135.67
Price to Sales1.97
Price to Book Ratio1.84
Enterprise Value to Revenue2.19
Enterprise Value to EBIT9.82
Enterprise Value to Net Income18
Total Debt to Enterprise0.15
Debt to Equity0.3

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Sanofi

CEO: Paul Hudson

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the c...